菜单
CRO Services

Drug Development Expertise Empowering Research Services for Biologics


Speak With Our Experts

PK/PD Services

Science-Driven In Vivo PK/PD Studies Across Mouse, Rat, and NHP Models for Preclinical Research

WuXi Biologics CRO Services provides one-stop, multi-species in vivo PK/PD services for preclinical research. Our end-to-end platform spans large-scale protein production, zero lead time for animal scheduling, in vivo dosing and sampling, and ex vivo bioanalysis for efficient PK/PD studies and data-driven preclinical decisions.

 

Speak with Our PK/PD Team

Fill out a short form to connect with our experts

 

Core Strength

PK/PD Services Highlights:

Science-Driven PK Analysis Services

Across mouse, rat, NHP, canine, and swine models

Customized PK/PD Assay Development

Utilizing ELISA, MSD, LC-MS, and HTRF analytical platforms

NHP Studies in 6-11 Weeks

Zero lead time from gram-level expression to animal scheduling and PK/PD studies

hFcRn Mouse PK Model Expertise

A reliable, cost-effective option for Fc engineering assessment


~ 500

Mouse studies delivered annually

~ 400

NHP naïve & non-naïve projects annually

200 +

Validated efficacy models

Service Details

PK/PD Service Details

Service Item Description Deliverables Turnaround
Mouse, Rat, NHP, Canine, and Swine PK Support exposure assessment, half-life evaluation, and clearance analysis
  • Serum/plasma concentration of total IgG, total Ab, total ADC, or free payload
  • PK parameters including t1/2, clearance, AUC, etc.
6–8 weeks
Immunophenotyping Characterize immune cell dynamics and biomarker-defined target cell changes over time
  • % of T/B/NK/Myeloid cells at different time points
  • % of targeted cells at different time points (specify biomarkers)
5–6 weeks
Receptor Occupancy Studies Measure target engagement and generate decision-ready PD insights
  • % of occupied targeted cells at different time points
5–6 weeks
Case Studies

Case Studies: PK/PD Services for Preclinical In Vivo Studies

Full Panel Pharmacokinetics (PK) Assay Workflow for Antibody & ADC Analysis

This case study highlights a full-panel PK assay development strategy for multi-species preclinical studies in rat, mouse, and NHP PK analysis models. The workflow supports total antibody, total ADC, and average DAR/free drug analysis using fit-for-purpose platforms like ELISA, HTRF, MSD, and LC-MS, helping generate actionable pharmacokinetics testing data.

Figure showing a full-panel PK assay workflow across rat, mouse, and NHP PK studies, with methods for total antibody, total ADC, and average DAR/free drug analysis using ELISA, HTRF, MSD, and LC-MS, with example concentration-time profiles for Fc-Fc, Fc-payload, and DAR assessment.

One-Stop In Vivo NHP PK/PD Analysis of TCE Activity +

This case study highlights a one-stop TCE NHP PK/PD evaluation combining exposure, immune cell dynamics, and tissue-level pharmacology. The TCE study showed rapid B cell depletion, increased T cell expansion, and enhanced tumor T cell infiltration, supporting mechanism-based assessment of TCE activity in vivo.

Figure showing integrated TCE NHP PK/PD data, including dose-dependent PK curves, rapid B cell depletion, T cell expansion over time, representative tumor staining images, and quantified T cell infiltration compared across treatment groups.

hFcRn Mouse PK Study for Fc Engineering Evaluation +

This case study highlights the use of hFcRn mice to evaluate Fc engineering effects on antibody PK analysis. Compared with the wild-type antibody, the Fc-engineered variant showed improved exposure over time, while gene background analysis confirmed a clean hFCGRT model to support reliable PK studies.

Figure showing PK curves in hFcRn mice comparing a wild-type antibody and an Fc-engineered variant, alongside gel images confirming a clean hFCGRT gene background with mFCGRT, hFCGRT, and control GAPDH bands.

Why WuXi Biologics

Why Work with WuXi Biologics for PK/PD Studies

  • Science-Driven PK/PD Support: From gram-level protein generation and animal scheduling to in vivo studies
  • Multi-Species Capability: Across mouse, rat, and NHP models for pharmacokinetics services
  • Broad Modality Experience: To support mAbs, bsAbs, ADCs, and other large molecules
  • Expert Data Analysis & Interpretation: Enabling informed decision-making

Get Started

 

Move from PK/PD Data to Better Preclinical Decisions

Advance your ADC and TCE projects with WuXi Biologics’ PK/PD services via murine/NHP species. From pharmacokinetic studies to immunophenotyping and receptor occupancy studies, we help you move from rational study design to decision-ready data with speed, flexibility, and expert support.